Thuesen L, Christiansen J S, Sørensen K E, Jørgensen J O, Orskov H, Henningsen P
University Department of Cardiology, Arhus Kommunehospital, Denmark.
Dan Med Bull. 1988 Apr;35(2):193-6.
Cardiac function was studied by echocardiography in 11 normal subjects before subcutaneous growth hormone administration (first control), after one week of subcutaneous growth hormone administration and at one week after stopping subcutaneous growth hormone administration (second control). Plasma growth hormone was 1.4 ng/ml and 4.5 ng/ml, respectively, at the first two examinations. Compared to the first and second control situations heart rate increased by 9% (p less than 0.1) and 15% (p less than 0.01), fractional shortening of the left ventricle by 8% (p less than 0.02) and 9% (p less than 0.01), and mean circumferential shortening velocity by 10% (p less than 0.05) and 14% (p less than 0.01) respectively. Mean arterial blood pressure was unchanged. Thus, in normal man an increase in plasma growth hormone up to levels comparable to those seen in type 1 diabetics during conditions of poor metabolic control seems to be followed by enhancement in myocardial contractility. Therefore we suggest that growth hormone might contribute to the increase of myocardial contractility earlier described in type 1 diabetic patients with no clinical signs of microvascular disease.
通过超声心动图对11名正常受试者在皮下注射生长激素前（首次对照）、皮下注射生长激素一周后以及停止皮下注射生长激素一周后（第二次对照）的心脏功能进行了研究。在前两次检查时，血浆生长激素水平分别为1.4 ng/ml和4.5 ng/ml。与首次和第二次对照情况相比，心率分别增加了9%（p<0.1）和15%（p<0.01），左心室缩短分数分别增加了8%（p<0.02）和9%（p<0.01），平均圆周缩短速度分别增加了10%（p<0.05）和14%（p<0.01）。平均动脉血压未发生变化。因此，在正常男性中，血浆生长激素升高至与1型糖尿病患者代谢控制不佳时相当的水平后，心肌收缩力似乎会增强。所以我们认为，生长激素可能促成了此前所描述的无微血管疾病临床体征的1型糖尿病患者心肌收缩力的增加。
